AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 985 participants.
Also called NCT07400107
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 985 participants
- Sponsor
- Registry
-
NCT07400107
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Bulgaria, Croatia, Germany, Hungary, India, Mexico, Poland, Portugal, Romania, Thailand, Türkiye
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07400107. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-20 (actual); primary completion 2028-12-19 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- Acronym
- AMAZE 8
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- NNC0487-0111
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (matched to NNC0487-0111)
- Intervention (Drug)
- Placebo (matched to semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07400107- Content hash
aaa731bbf5e12566921af013e0b6159badc008563e18b0a663981b0ad814ffe0